Journal article
Molecular imaging and quantitation of EphA2 expression in xenograft models with 89Zr-DS-8895a
IJG Burvenich, S Parakh, HK Gan, FT Lee, N Guo, A Rigopoulos, ST Lee, S Gong, GJ O'Keefe, H Tochon-Danguy, M Kotsuma, J Hasegawa, G Senaldi, AM Scott
Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2016
Abstract
Subtype A2 of the erythropoietin-producing hepatocellular tyrosine kinase (EphA2) cell surface receptor is expressed in a range of epithelial cancers. This study evaluated the molecular imaging of EphA2 expression in vivo in mouse tumor models using SPECT/MR and PET/MR and a humanized anti-EphA2 antibody, DS-8895a. Methods: DS-8895a was labeled with 111In, 125I, and 89Zr and assessed for radiochemical purity, immunoreactivity (Lindmo analysis), antigen-binding affinity (Scatchard analysis), and serum stability in vitro. In vivo biodistribution, imaging, and pharmacokinetic studies were performed with SPECT/MR and PET/MR. A dose-escalation study was also performed to determine EphA2 receptor ..
View full abstractGrants
Funding Acknowledgements
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This work was supported by funding from Daiichi-Sankyo Co., Ltd., by the Operational Infrastructure Support program of the Victorian State Government, and by the Solid Target Laboratory, an ANSTO-Austin-LICR Partnership. We acknowledge the Australian Cancer Research Foundation for providing funds to purchase the small-animal PET/MR and SPECT/CT imaging equipment. Masakatsu Kotsuma, Jun Hasegawa, and Giorgio Senaldi are employees of Daiichi-Sankyo Co., Ltd. No other potential conflict of interest relevant to this article was reported.